These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27524636)

  • 1. Anti-infective Dosing for Obese Adult Patients: A Focus on Newer Drugs to Treat Methicillin-resistant Staphylococcus aureus Acute Bacterial Skin and Skin Structure Infections.
    Pai MP
    Clin Ther; 2016 Sep; 38(9):2032-44. PubMed ID: 27524636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
    Ocheretyaner ER; Park TE
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):523-530. PubMed ID: 29911455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
    Esposito S; Noviello S; Leone S
    Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Jorgenson MR; DePestel DD; Carver PL
    Ann Pharmacother; 2011 Nov; 45(11):1384-98. PubMed ID: 22009993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital Pharmacometrics for Optimal Individual Administration of Antimicrobial Agents for Anti-methicillin-resistant Staphylococcus aureus Infected Patients.
    Tsuji Y
    Biol Pharm Bull; 2021; 44(9):1174-1183. PubMed ID: 34471044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
    Soriano A; Rossolini GM; Pea F
    Expert Rev Anti Infect Ther; 2020 May; 18(5):415-422. PubMed ID: 32223465
    [No Abstract]   [Full Text] [Related]  

  • 7. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
    Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
    J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.
    Drusano GL
    J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv33-9. PubMed ID: 21115453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.
    Stein GE; Wells EM
    Curr Med Res Opin; 2010 Mar; 26(3):571-88. PubMed ID: 20055750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?
    Grupper M; Nicolau DP
    Curr Opin Infect Dis; 2017 Apr; 30(2):180-191. PubMed ID: 28118218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.
    McCool R; Gould IM; Eales J; Barata T; Arber M; Fleetwood K; Glanville J; Kauf TL
    BMC Infect Dis; 2017 Jan; 17(1):39. PubMed ID: 28061827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines.
    Moran GJ; Abrahamian FM; Lovecchio F; Talan DA
    J Emerg Med; 2013 Jun; 44(6):e397-412. PubMed ID: 23466022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Puzniak LA; Morrow LE; Huang DB; Barreto JN
    Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's new in the treatment of serious MRSA infection?
    Holmes NE; Howden BP
    Curr Opin Infect Dis; 2014 Dec; 27(6):471-8. PubMed ID: 25211361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options).
    Payne KD; Das A; Ndiulor M; Hall RG
    Expert Rev Clin Pharmacol; 2018 Feb; 11(2):139-149. PubMed ID: 29186999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
    Huang DB; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Desplats E; Torres A
    Int J Antimicrob Agents; 2018 Aug; 52(2):233-240. PubMed ID: 29783024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
    Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
    Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging drugs for acute bacterial skin and skin structure infections: an update.
    Kollipara R; Downing C; Lee M; Guidry J; Curtis S; Tyring S
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):431-40. PubMed ID: 25146459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New antibiotics in the management of acute bacterial skin and skin structure infections.
    Gleghorn K; Grimshaw E; Kelly EK
    Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).
    Hall RG; Thatcher M; Wei W; Varghese S; Varughese L; Ndiulor M; Payne KD
    Expert Rev Clin Pharmacol; 2017 May; 10(5):493-508. PubMed ID: 28293964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.